NAGLU and mucopolysaccharidosis type 3B: The interaction of a set of four <i>N</i>-acetyl-glucosamine (GlcNAc) glycomimetics with human <i>N</i>-acetyl-glucosaminidase (NAGLU), the genetically defective enzyme in patients suffering from mucopolysaccharidosis (MPS) IIIB, also known as Sanfilippo B syndrome, was investigated to identify potential pharmacological chaperones.